津力达联合甘精胰岛素治疗初诊2型糖尿病患者的临床效果

目的观察津力达联合甘精胰岛素治疗初诊2型糖尿病患者(HbA1c9.0%)的临床疗效。方法选取我院2017年5月～2018年1月内分泌科收治的60例初诊2型糖尿病患者,按照随机数字表法分为治疗组(A组,30例)与对照组(B组,30例),A组患者给予津力达联合甘精胰岛素治疗,B组患者给予二甲双胍联合甘精胰岛素分别治疗24周。比较两组患者治疗前后血糖、糖化血红蛋白、体质指数、胰岛素抵抗的变化及甘精胰岛素的使用剂量及不良反应的发生情况。结果两组患者治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白、体质指数及胰岛素抵抗指数低于治疗前,而空腹胰岛素水平及胰岛功能高于治疗前水平,差异具有统计学意义(P0.05)。两组患者治疗后各指标比较,差异无统计学意义(P0.05),两组患者甘精胰岛素的使用剂量无显著差异(P0.05),且均未发生严重的不良反应。结论津力达联合甘精胰岛素可改善初诊2型糖尿病患者(HbA1c9.0%)的血糖控制、体重指数、胰岛素功能及敏感性,与二甲双胍联合甘精胰岛素的治疗具有相似的疗效及安全性,可以作为临床的治疗2型糖尿病的有效方案。

Clinical effect of Jin Lida combined with insulin glargine in the treatment of newly diagnosed type 2 diabetes patients

Objective To observe the clinical efficacy of Jin Lida combined with insulin glargine in the treatment of newly diagnosed type 2 diabetes patients(HbA1c>9.0%).Methods A total of 60 patients with newly diagnosed type 2 diabetes admitted in the Department of Endocrinology from May 2017 to January 2018 were enrolled.The patients were divided into treatment group(group A,30 cases)and control group(group B,30 cases)according to the random number table.Patients in group A were treated with Jin Lida and insulin glargine,and patients in group B were treated with metformin and insulin glargine for 24 weeks.The changes of blood glucose,glycosylated hemoglobin,body mass index and the changes of insulin resistance index before and after treatment were compared between the two groups.The dose of insulin glargine and the incidence of adverse reactions were compared.Results The fasting blood glucose,postprandial 2 h blood glucose,glycosylated hemoglobin,body mass index and insulin resistance index of the two groups after treatment were lower than those before treatment,while fasting insulin level and islet function after treatment were higher than the pre-treatment level.The difference was statistically significant(P<0.05).There were no significant differences in the indexes between the two groups after treatment(P>0.05).There was no significant difference in the doses of insulin glargine between the two groups(P>0.05),and no serious adverse reactions occurred.Conclusion Jin Lida combined with insulin glargine can improve curative effect on glycemic control,body mass index,insulin function and sensitivity in newly diagnosed type 2 diabetic patients(HbA1c>9.0%),and has similar efficacy and safety in treatment with metformin combined with insulin glargine.And it can be used as an effective treatment for type 2 diabetes in the clinic.